Touch Bionics announced that preliminary results indicate the company achieved revenue growth of 23 percent in 2013 to reach £12.3 million (about US $20.25 million, as reported this date) in total sales.
The company said its growth was driven by the introduction of the i-limb ultra revolution. The company also introduced biosim and my i-limb mobile applications, which enable clinicians and patients to easily program the features of an i-limb via a handheld mobile device.
“We are pleased with our 2013 performance and are looking forward to continued growth in 2014,” said Ian Stevens, CEO of Touch Bionics.
